Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Versartis Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $60 million follow-on offering of 4,898,000 shares…
Davis Polk Advises AC Immune SA on Its Initial Public Offering
Davis Polk advised AC Immune SA in connection with its $75.9 million U.S. initial public offering. AC Immune sold 6,900,000…
Davis Polk Advises Shire plc on Its $12.1 Billion Notes Offering
Davis Polk advised Shire plc on the $12.1 billion SEC-registered debt offering by its wholly owned subsidiary, Shire…
Evolent Health Secondary Offering
Davis Polk advised the representatives of the several underwriters, in connection with a secondary offering of 7,500,000…
OncoMed Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the sole book-running manager and representative of the several underwriters in connection with a $63.3…
Pfizer Acquires Medivation
Davis Polk is advising J.P. Morgan Securities as financial adviser to Medivation, Inc. in connection with its approximately …
Davis Polk Advises Aetna on the Sale of Medicare Advantage Assets to Molina Healthcare
Davis Polk is advising Aetna Inc. in connection with the sale by Aetna and Humana Inc. of certain of their respective…
Laboratory Corporation of America Holdings Acquires Sequenom, Inc.
Davis Polk is advising JP Morgan as financial adviser to Sequenom, Inc. in connection with its $371 million acquisition by…
Patheon N.V. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $719 million…
Intercept Pharmaceuticals, Inc. $460 Million Convertible Senior Notes Offering
Davis Polk acted as special product counsel to the representatives of the initial purchasers in connection with an SEC…